Английская Википедия:Intepirdine

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Intepirdine (INN; developmental codes SB-742457, RVT-101)[1] is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects.[2][3] It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials.[3] GSK chose not to continue development and sold the rights to Axovant Sciences for $5 million in December 2014.[4]

Results of a phase III clinical trial for the treatment of Alzheimer's disease were reported in September 2017.[5] The trial showed no improvement over control group and Axovant lost 70% of its value upon the announcement of the trial results.[6]

Intepirdine also entered clinical trials for dementia with Lewy bodies, also with negative results.[7] Consequently, Axovant announced in 2018 that it has discontinued development of this drug.[7]

References

Шаблон:Reflist

Шаблон:Antidementia

Шаблон:Serotonergics